Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor [PDF]
Yeungnam University Journal of Medicine, 2019 Imatinib mesylate is currently used as the first-line treatment for metastatic gastrointestinal stromal tumors (GISTs). Imatinib-induced hepatotoxicity in patients with GIST is very rare.
Min Kyu Kang +2 more
doaj +1 more source
Blue nails in chronic myeloid leukemia Is it usual?
National Journal of Physiology, Pharmacy and Pharmacology, 2020 Nail toxicity is an uncommon cutaneous adverse effect of imatinib mesylate. Here, we have described a 45-year-old female, a diagnosed case of Philadelphia positive chronic myeloid leukemia, who was on imatinib mesylate for the past 3 months and developed
Jaydeep Raj Damor +7 more
doaj +1 more source
Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience [PDF]
Vojnosanitetski Pregled, 2010 Background/Aim. Imatinib mesylate, a tyrosine kinase inhibitor with specific activity against the breakpoint cluster region - Abelson murine leukemia (BCR-ABL) tyrosine kinase has been developed for treatment of chronic myelogenous leukemia (CML).
Ćojbašić Irena +1 more
doaj +1 more source
Paraneoplastic hypoglycaemia secondary to IGF-2 secretion from a metastatic gastrointestinal stromal tumour [PDF]
, 2020 We report the case of a 79-year-old male with previous history of non-Hodgkin's lymphoma in remission, who presented acutely to the Accident and Emergency department with recurrent episodes of hypoglycaemia.
Dimitriadis, Georgios K. +9 more
core +1 more source
Protein kinase Cδ and c-Abl kinase are required for transforming growth factor β induction of endothelial-mesenchymal transition in vitro. [PDF]
, 2011 OBJECTIVE: The origin of the mesenchymal cells responsible for the intimal fibrosis in systemic sclerosis (SSc) has not been fully identified. The present study was undertaken to investigate whether subendothelial mesenchymal cells may emerge through ...
Jimenez, Sergio A., Li, zhaodong
core +2 more sources
PLoS ONE, 2014 Osteosarcoma is the most common primary malignant bone tumour characterized by osteoid production and/or osteolytic lesions of bone. A lack of response to chemotherapeutic treatments shows the importance of exploring new therapeutic methods.
Bérengère Gobin +7 more
doaj +1 more source
A rare case of melanosis of the hard palate mucosa in a patient with chronic myeloid leukemia [PDF]
, 2015 Imatinib Mesylate, also known as Gleevec or ST1-571, is a tyrosine-kinase inhibitor used as the gold standard medication for the chronic myeloid leukemia (CML); Imatinib has indeed deeply revolutionized the CML therapy allowing most patients to have a ...
Bosco, Daniela +4 more
core +3 more sources
Role for targeted resection in the multidisciplinary treatment of metastatic gastrointestinal stromal tumor [PDF]
, 2019 The management of advanced gastrointestinal stromal tumors (GISTs) has evolved in the modern era due to the discovery of c-kit mutations and the development of tyrosine kinase inhibitors (TKIs).
Feizpour, Cyrus +4 more
core +1 more source
Postoperative Cure for Metastatic Gastrointestinal Stromal Tumor
The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2018 Gastrointestinal stromal tumor (GIST) is a mesenchymal tumor derived from Cajal cells originating from the myotonic plexus. The expression of tyrosine kinase (KIT) membrane receptors that are active on KIT is inhibited by the KIT inhibitor imatinib ...
Eun Hyea Park +3 more
doaj +1 more source
SUCCINATE DEHYDROGENASE SUBUNIT B DEFICIENT PEDIATRIC GIST
Hematology, Transfusion and Cell Therapy, 2022 Case report Gastrointestinal stromal tumors (GISTs) occur exceedingly rare in children and adolescents. Eighty five percent of pediatric GISTs and 15 % of adult GISTs lack oncogenic mutations in KIT and PDGFRA.
Melek Yaman Ortakoylu +5 more
doaj +1 more source